| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 141 | 2022 | 861 | 23.600 |
Why?
|
| Acute Coronary Syndrome | 37 | 2021 | 250 | 10.520 |
Why?
|
| Hospitalization | 100 | 2022 | 1290 | 9.920 |
Why?
|
| Heart Failure | 66 | 2023 | 853 | 8.840 |
Why?
|
| Hospital Mortality | 67 | 2022 | 841 | 7.100 |
Why?
|
| Aged | 281 | 2025 | 13405 | 5.970 |
Why?
|
| Massachusetts | 108 | 2023 | 2019 | 5.790 |
Why?
|
| Male | 303 | 2024 | 27742 | 4.710 |
Why?
|
| Female | 320 | 2025 | 30719 | 4.610 |
Why?
|
| Atrial Fibrillation | 33 | 2024 | 805 | 4.300 |
Why?
|
| Middle Aged | 221 | 2025 | 16310 | 4.190 |
Why?
|
| Patient Discharge | 22 | 2019 | 490 | 4.160 |
Why?
|
| Practice Patterns, Physicians' | 25 | 2020 | 692 | 4.120 |
Why?
|
| Aged, 80 and over | 121 | 2025 | 5119 | 4.050 |
Why?
|
| Humans | 368 | 2025 | 59366 | 3.700 |
Why?
|
| Risk Factors | 107 | 2024 | 4986 | 3.680 |
Why?
|
| Venous Thromboembolism | 18 | 2020 | 145 | 3.360 |
Why?
|
| Patient Readmission | 14 | 2021 | 420 | 3.350 |
Why?
|
| Stroke Volume | 18 | 2023 | 314 | 3.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 22 | 2022 | 142 | 3.250 |
Why?
|
| Shock, Cardiogenic | 13 | 2022 | 85 | 2.910 |
Why?
|
| Risk Assessment | 40 | 2022 | 1925 | 2.810 |
Why?
|
| Incidence | 51 | 2025 | 1238 | 2.780 |
Why?
|
| Prognosis | 47 | 2022 | 1597 | 2.710 |
Why?
|
| Inpatients | 12 | 2019 | 291 | 2.710 |
Why?
|
| Survivors | 9 | 2019 | 149 | 2.680 |
Why?
|
| Time Factors | 59 | 2019 | 3615 | 2.580 |
Why?
|
| Adrenergic beta-Antagonists | 19 | 2019 | 147 | 2.510 |
Why?
|
| Age Factors | 42 | 2021 | 1504 | 2.510 |
Why?
|
| Quality of Life | 20 | 2024 | 1137 | 2.280 |
Why?
|
| Length of Stay | 16 | 2019 | 776 | 2.280 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2022 | 160 | 2.260 |
Why?
|
| Cardiac Catheterization | 10 | 2022 | 253 | 2.240 |
Why?
|
| Anticoagulants | 20 | 2024 | 480 | 2.220 |
Why?
|
| Cardiovascular Agents | 11 | 2017 | 98 | 2.190 |
Why?
|
| Retrospective Studies | 72 | 2024 | 6069 | 2.180 |
Why?
|
| Multiple Chronic Conditions | 5 | 2023 | 37 | 2.130 |
Why?
|
| Treatment Outcome | 71 | 2024 | 5281 | 2.120 |
Why?
|
| Platelet Aggregation Inhibitors | 12 | 2021 | 211 | 2.000 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2022 | 64 | 1.990 |
Why?
|
| Patient Acceptance of Health Care | 11 | 2020 | 454 | 1.970 |
Why?
|
| Diabetes Mellitus | 11 | 2023 | 515 | 1.960 |
Why?
|
| Coronary Artery Bypass | 16 | 2022 | 275 | 1.900 |
Why?
|
| Prospective Studies | 43 | 2023 | 3067 | 1.860 |
Why?
|
| Multivariate Analysis | 36 | 2019 | 902 | 1.850 |
Why?
|
| Stroke | 26 | 2023 | 1127 | 1.850 |
Why?
|
| Electrocardiography | 18 | 2017 | 521 | 1.800 |
Why?
|
| Cardiovascular Diseases | 14 | 2020 | 788 | 1.780 |
Why?
|
| Follow-Up Studies | 35 | 2023 | 2338 | 1.770 |
Why?
|
| Registries | 36 | 2025 | 799 | 1.740 |
Why?
|
| Logistic Models | 34 | 2021 | 1235 | 1.740 |
Why?
|
| Myocardial Revascularization | 9 | 2019 | 71 | 1.700 |
Why?
|
| Disease Management | 7 | 2019 | 220 | 1.670 |
Why?
|
| ST Elevation Myocardial Infarction | 5 | 2022 | 73 | 1.670 |
Why?
|
| Sex Factors | 29 | 2020 | 935 | 1.670 |
Why?
|
| Survival Rate | 21 | 2019 | 801 | 1.660 |
Why?
|
| Aspirin | 14 | 2021 | 167 | 1.620 |
Why?
|
| Comorbidity | 33 | 2020 | 1078 | 1.570 |
Why?
|
| Odds Ratio | 30 | 2021 | 747 | 1.560 |
Why?
|
| Graves Ophthalmopathy | 3 | 2018 | 6 | 1.520 |
Why?
|
| Coronary Disease | 12 | 2014 | 244 | 1.470 |
Why?
|
| Thrombolytic Therapy | 12 | 2019 | 184 | 1.470 |
Why?
|
| Emergency Medical Services | 8 | 2016 | 255 | 1.470 |
Why?
|
| Hypertension | 13 | 2024 | 568 | 1.450 |
Why?
|
| Religion | 3 | 2019 | 29 | 1.430 |
Why?
|
| Ventricular Function, Left | 9 | 2015 | 257 | 1.420 |
Why?
|
| Acute Disease | 28 | 2015 | 658 | 1.410 |
Why?
|
| Population Surveillance | 10 | 2015 | 195 | 1.390 |
Why?
|
| Angioplasty, Balloon, Coronary | 15 | 2014 | 168 | 1.340 |
Why?
|
| Hyperglycemia | 4 | 2018 | 98 | 1.300 |
Why?
|
| Venous Thrombosis | 6 | 2014 | 110 | 1.300 |
Why?
|
| Adult | 77 | 2025 | 15679 | 1.290 |
Why?
|
| Frailty | 8 | 2023 | 124 | 1.290 |
Why?
|
| Research Design | 10 | 2017 | 555 | 1.280 |
Why?
|
| Hemorrhage | 16 | 2024 | 260 | 1.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2024 | 725 | 1.260 |
Why?
|
| Transportation of Patients | 4 | 2018 | 42 | 1.230 |
Why?
|
| Glucose Tolerance Test | 3 | 2013 | 96 | 1.220 |
Why?
|
| Residence Characteristics | 7 | 2013 | 215 | 1.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 10 | 2016 | 204 | 1.190 |
Why?
|
| Diabetes, Gestational | 4 | 2015 | 138 | 1.170 |
Why?
|
| Anemia | 3 | 2019 | 119 | 1.150 |
Why?
|
| Tachycardia, Ventricular | 3 | 2018 | 119 | 1.130 |
Why?
|
| Diabetes Complications | 5 | 2014 | 100 | 1.130 |
Why?
|
| Evidence-Based Medicine | 7 | 2019 | 442 | 1.120 |
Why?
|
| United States | 53 | 2024 | 7426 | 1.120 |
Why?
|
| Vietnam | 16 | 2025 | 165 | 1.100 |
Why?
|
| Angina, Unstable | 13 | 2009 | 57 | 1.100 |
Why?
|
| Ventricular Fibrillation | 4 | 2019 | 97 | 1.090 |
Why?
|
| Body Mass Index | 6 | 2021 | 831 | 1.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2023 | 657 | 1.080 |
Why?
|
| Prevalence | 25 | 2024 | 1253 | 1.080 |
Why?
|
| Cross-Sectional Studies | 30 | 2024 | 2380 | 1.070 |
Why?
|
| Anxiety Disorders | 2 | 2018 | 187 | 1.070 |
Why?
|
| School Health Services | 3 | 2022 | 60 | 1.060 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 5 | 2018 | 30 | 1.060 |
Why?
|
| Biomedical Research | 4 | 2019 | 256 | 1.050 |
Why?
|
| Chi-Square Distribution | 15 | 2017 | 409 | 1.040 |
Why?
|
| Survival Analysis | 20 | 2019 | 554 | 1.040 |
Why?
|
| Georgia | 10 | 2020 | 87 | 1.030 |
Why?
|
| Blood Glucose | 6 | 2021 | 461 | 1.030 |
Why?
|
| Nutrition Surveys | 5 | 2021 | 130 | 1.020 |
Why?
|
| Chest Pain | 7 | 2020 | 81 | 1.020 |
Why?
|
| Sex Distribution | 14 | 2019 | 244 | 1.020 |
Why?
|
| Blood Pressure | 8 | 2023 | 495 | 1.020 |
Why?
|
| Decompression, Surgical | 2 | 2018 | 61 | 1.010 |
Why?
|
| Mortality | 8 | 2019 | 155 | 0.990 |
Why?
|
| Healthcare Disparities | 6 | 2023 | 330 | 0.980 |
Why?
|
| Age Distribution | 14 | 2019 | 250 | 0.960 |
Why?
|
| Hypolipidemic Agents | 4 | 2019 | 25 | 0.960 |
Why?
|
| Forecasting | 3 | 2017 | 220 | 0.950 |
Why?
|
| Clinical Trials as Topic | 5 | 2021 | 440 | 0.950 |
Why?
|
| Health Services Accessibility | 5 | 2018 | 527 | 0.950 |
Why?
|
| Cohort Studies | 24 | 2024 | 2375 | 0.950 |
Why?
|
| Drug Utilization | 7 | 2019 | 208 | 0.940 |
Why?
|
| Kidney Diseases | 5 | 2016 | 169 | 0.940 |
Why?
|
| Cause of Death | 11 | 2019 | 210 | 0.930 |
Why?
|
| Patient Selection | 5 | 2017 | 465 | 0.920 |
Why?
|
| Fibrinolytic Agents | 9 | 2012 | 163 | 0.920 |
Why?
|
| Glomerular Filtration Rate | 6 | 2013 | 101 | 0.910 |
Why?
|
| Health Education | 2 | 2016 | 183 | 0.900 |
Why?
|
| Aging | 6 | 2020 | 710 | 0.880 |
Why?
|
| Secondary Prevention | 9 | 2021 | 151 | 0.870 |
Why?
|
| Urban Population | 5 | 2015 | 180 | 0.850 |
Why?
|
| Diagnostic Imaging | 3 | 2014 | 243 | 0.830 |
Why?
|
| Heart Block | 3 | 2009 | 22 | 0.830 |
Why?
|
| Proportional Hazards Models | 18 | 2021 | 674 | 0.810 |
Why?
|
| Surveys and Questionnaires | 19 | 2024 | 2516 | 0.810 |
Why?
|
| Brain Injuries | 2 | 2015 | 135 | 0.800 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2020 | 677 | 0.800 |
Why?
|
| Echocardiography | 6 | 2022 | 457 | 0.800 |
Why?
|
| Life Style | 6 | 2024 | 299 | 0.790 |
Why?
|
| Medicare | 11 | 2024 | 601 | 0.790 |
Why?
|
| Pulmonary Embolism | 7 | 2014 | 169 | 0.790 |
Why?
|
| Rural Population | 4 | 2024 | 188 | 0.780 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2019 | 158 | 0.780 |
Why?
|
| School Nursing | 2 | 2022 | 26 | 0.770 |
Why?
|
| Intensive Care Units | 4 | 2020 | 423 | 0.760 |
Why?
|
| Diet | 5 | 2022 | 496 | 0.760 |
Why?
|
| Guideline Adherence | 5 | 2023 | 292 | 0.760 |
Why?
|
| Decision Support Techniques | 6 | 2020 | 180 | 0.750 |
Why?
|
| Asthma | 4 | 2022 | 457 | 0.750 |
Why?
|
| Oculomotor Muscles | 2 | 2018 | 10 | 0.740 |
Why?
|
| Body Weight | 2 | 2014 | 368 | 0.740 |
Why?
|
| Smoking Cessation | 2 | 2020 | 541 | 0.730 |
Why?
|
| Resuscitation Orders | 4 | 2016 | 48 | 0.720 |
Why?
|
| Longitudinal Studies | 14 | 2021 | 1189 | 0.720 |
Why?
|
| Patient Participation | 4 | 2019 | 216 | 0.720 |
Why?
|
| Awareness | 3 | 2020 | 74 | 0.710 |
Why?
|
| Case-Control Studies | 11 | 2024 | 1051 | 0.710 |
Why?
|
| Medication Adherence | 4 | 2022 | 241 | 0.690 |
Why?
|
| Ambulances | 2 | 2012 | 24 | 0.680 |
Why?
|
| Primary Prevention | 6 | 2021 | 134 | 0.680 |
Why?
|
| Smoking | 4 | 2024 | 826 | 0.670 |
Why?
|
| Diuretics | 4 | 2016 | 59 | 0.670 |
Why?
|
| Calcium Channel Blockers | 3 | 2019 | 56 | 0.670 |
Why?
|
| Sample Size | 2 | 2017 | 61 | 0.670 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2021 | 145 | 0.660 |
Why?
|
| Religion and Medicine | 1 | 2019 | 17 | 0.650 |
Why?
|
| Patient Admission | 2 | 2018 | 184 | 0.650 |
Why?
|
| Myocardial Reperfusion | 4 | 2010 | 24 | 0.640 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2019 | 12 | 0.640 |
Why?
|
| Multimorbidity | 7 | 2023 | 43 | 0.640 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2019 | 13 | 0.640 |
Why?
|
| Coronary Artery Disease | 7 | 2014 | 274 | 0.630 |
Why?
|
| Data Collection | 6 | 2019 | 371 | 0.630 |
Why?
|
| Circadian Rhythm | 2 | 2013 | 373 | 0.630 |
Why?
|
| Vaping | 1 | 2020 | 44 | 0.630 |
Why?
|
| Firearms | 1 | 2020 | 54 | 0.620 |
Why?
|
| Statistics as Topic | 1 | 2019 | 146 | 0.620 |
Why?
|
| Economics | 1 | 2018 | 7 | 0.610 |
Why?
|
| Drug Prescriptions | 5 | 2019 | 168 | 0.590 |
Why?
|
| Students | 2 | 2020 | 202 | 0.590 |
Why?
|
| Communication Barriers | 1 | 2018 | 56 | 0.590 |
Why?
|
| Perception | 3 | 2022 | 168 | 0.580 |
Why?
|
| Warfarin | 2 | 2019 | 105 | 0.570 |
Why?
|
| Meta-Analysis as Topic | 2 | 2015 | 77 | 0.560 |
Why?
|
| Hospital Administration | 2 | 2014 | 41 | 0.560 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 1479 | 0.560 |
Why?
|
| Recurrence | 9 | 2016 | 602 | 0.550 |
Why?
|
| Outpatients | 3 | 2022 | 137 | 0.550 |
Why?
|
| Self-Management | 1 | 2018 | 55 | 0.550 |
Why?
|
| Eyelids | 2 | 2018 | 7 | 0.540 |
Why?
|
| Predictive Value of Tests | 15 | 2019 | 1027 | 0.540 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 50 | 0.540 |
Why?
|
| Feeding Behavior | 4 | 2015 | 254 | 0.530 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 168 | 0.520 |
Why?
|
| Exercise | 3 | 2022 | 883 | 0.510 |
Why?
|
| Critical Care | 4 | 2017 | 397 | 0.510 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 8 | 0.510 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 42 | 0.510 |
Why?
|
| Depressive Disorder | 1 | 2018 | 279 | 0.500 |
Why?
|
| Review Literature as Topic | 1 | 2015 | 33 | 0.500 |
Why?
|
| Decision Making | 3 | 2017 | 395 | 0.500 |
Why?
|
| Administration, Oral | 7 | 2024 | 355 | 0.490 |
Why?
|
| Lung Diseases | 2 | 2017 | 170 | 0.490 |
Why?
|
| Weight Loss | 2 | 2014 | 263 | 0.480 |
Why?
|
| Urban Health | 3 | 2015 | 40 | 0.470 |
Why?
|
| Clinical Protocols | 1 | 2016 | 136 | 0.470 |
Why?
|
| Depression | 6 | 2023 | 829 | 0.470 |
Why?
|
| Orbital Cellulitis | 1 | 2014 | 1 | 0.470 |
Why?
|
| Orbital Myositis | 1 | 2014 | 1 | 0.470 |
Why?
|
| Orbit | 1 | 2014 | 15 | 0.470 |
Why?
|
| Blepharoplasty | 2 | 2012 | 5 | 0.450 |
Why?
|
| Temperament | 1 | 2014 | 20 | 0.440 |
Why?
|
| Anger | 1 | 2014 | 22 | 0.440 |
Why?
|
| Endpoint Determination | 1 | 2014 | 24 | 0.440 |
Why?
|
| Nursing Homes | 9 | 2024 | 661 | 0.440 |
Why?
|
| Electronic Health Records | 5 | 2023 | 342 | 0.430 |
Why?
|
| Databases, Factual | 9 | 2019 | 814 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 635 | 0.430 |
Why?
|
| Quality of Health Care | 4 | 2020 | 513 | 0.430 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 153 | 0.430 |
Why?
|
| Brain Injuries, Traumatic | 3 | 2020 | 84 | 0.420 |
Why?
|
| Thinness | 2 | 2011 | 40 | 0.420 |
Why?
|
| Self Report | 6 | 2022 | 359 | 0.420 |
Why?
|
| Hospitals | 4 | 2022 | 377 | 0.410 |
Why?
|
| Pediatric Obesity | 1 | 2014 | 96 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 164 | 0.410 |
Why?
|
| Medical Records | 6 | 2013 | 133 | 0.410 |
Why?
|
| Glucose Intolerance | 1 | 2013 | 88 | 0.400 |
Why?
|
| Geriatric Assessment | 6 | 2022 | 159 | 0.400 |
Why?
|
| Sex Characteristics | 1 | 2014 | 197 | 0.400 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 217 | 0.400 |
Why?
|
| Rejuvenation | 1 | 2012 | 2 | 0.390 |
Why?
|
| Health Promotion | 3 | 2012 | 471 | 0.390 |
Why?
|
| Central Nervous System Stimulants | 1 | 2012 | 63 | 0.380 |
Why?
|
| Leg | 1 | 2012 | 85 | 0.380 |
Why?
|
| Heart Rate | 6 | 2016 | 307 | 0.380 |
Why?
|
| Algorithms | 7 | 2016 | 974 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2019 | 396 | 0.380 |
Why?
|
| Prisons | 1 | 2012 | 105 | 0.380 |
Why?
|
| Metabolic Syndrome | 3 | 2011 | 131 | 0.380 |
Why?
|
| Smoking Prevention | 1 | 2012 | 158 | 0.370 |
Why?
|
| Heart Failure, Diastolic | 2 | 2011 | 9 | 0.370 |
Why?
|
| Heart Failure, Systolic | 2 | 2011 | 16 | 0.360 |
Why?
|
| Biomarkers | 7 | 2022 | 1306 | 0.360 |
Why?
|
| Hospitals, Community | 2 | 2009 | 70 | 0.360 |
Why?
|
| Dementia | 2 | 2024 | 248 | 0.360 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 156 | 0.350 |
Why?
|
| Overweight | 4 | 2014 | 238 | 0.350 |
Why?
|
| Drug Utilization Review | 2 | 2007 | 52 | 0.350 |
Why?
|
| Parents | 1 | 2014 | 367 | 0.350 |
Why?
|
| Adolescent | 13 | 2024 | 5835 | 0.340 |
Why?
|
| Anticholesteremic Agents | 2 | 2008 | 34 | 0.340 |
Why?
|
| Disease Progression | 6 | 2018 | 1119 | 0.330 |
Why?
|
| Critical Illness | 4 | 2020 | 325 | 0.330 |
Why?
|
| Myocardial Ischemia | 6 | 2007 | 111 | 0.330 |
Why?
|
| Obesity | 4 | 2011 | 1166 | 0.330 |
Why?
|
| Angiocardiography | 1 | 2009 | 6 | 0.330 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2007 | 47 | 0.330 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2009 | 11 | 0.330 |
Why?
|
| Hospitals, Teaching | 3 | 2016 | 101 | 0.330 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 34 | 0.330 |
Why?
|
| Cognition | 4 | 2022 | 454 | 0.330 |
Why?
|
| Noncommunicable Diseases | 2 | 2019 | 15 | 0.320 |
Why?
|
| Chronic Disease | 6 | 2023 | 717 | 0.310 |
Why?
|
| Spirituality | 2 | 2019 | 37 | 0.310 |
Why?
|
| Skilled Nursing Facilities | 3 | 2018 | 83 | 0.300 |
Why?
|
| Child | 10 | 2024 | 4187 | 0.300 |
Why?
|
| Antihypertensive Agents | 1 | 2010 | 162 | 0.300 |
Why?
|
| Health Services for the Aged | 1 | 2008 | 47 | 0.300 |
Why?
|
| Thromboembolism | 3 | 2018 | 69 | 0.300 |
Why?
|
| Defibrillators, Implantable | 3 | 2019 | 257 | 0.300 |
Why?
|
| Heart Atria | 1 | 2009 | 135 | 0.300 |
Why?
|
| Gastric Bypass | 1 | 2009 | 74 | 0.300 |
Why?
|
| Video-Assisted Surgery | 1 | 2008 | 10 | 0.300 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2009 | 158 | 0.300 |
Why?
|
| Socioeconomic Factors | 6 | 2017 | 742 | 0.290 |
Why?
|
| Models, Anatomic | 1 | 2008 | 60 | 0.290 |
Why?
|
| Young Adult | 12 | 2025 | 4273 | 0.290 |
Why?
|
| Patient Education as Topic | 6 | 2023 | 453 | 0.290 |
Why?
|
| Bronchoscopy | 1 | 2008 | 86 | 0.290 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 132 | 0.290 |
Why?
|
| Obesity, Morbid | 1 | 2009 | 92 | 0.290 |
Why?
|
| Women's Health | 4 | 2007 | 360 | 0.280 |
Why?
|
| Models, Biological | 1 | 2013 | 1143 | 0.280 |
Why?
|
| Causality | 1 | 2007 | 57 | 0.280 |
Why?
|
| Angina Pectoris | 2 | 2004 | 37 | 0.280 |
Why?
|
| Confidence Intervals | 5 | 2015 | 242 | 0.280 |
Why?
|
| Attitude to Health | 2 | 2015 | 279 | 0.280 |
Why?
|
| Morbidity | 2 | 2020 | 113 | 0.280 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 34 | 0.270 |
Why?
|
| Poverty Areas | 2 | 2013 | 15 | 0.270 |
Why?
|
| Regression Analysis | 9 | 2019 | 486 | 0.270 |
Why?
|
| Kidney | 2 | 2013 | 414 | 0.270 |
Why?
|
| Pregnancy | 6 | 2024 | 2213 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 4 | 2020 | 297 | 0.270 |
Why?
|
| Time | 2 | 2008 | 26 | 0.270 |
Why?
|
| Mass Screening | 2 | 2017 | 648 | 0.260 |
Why?
|
| Leukocyte Count | 3 | 2018 | 97 | 0.260 |
Why?
|
| Frail Elderly | 3 | 2022 | 107 | 0.260 |
Why?
|
| Troponin I | 3 | 2022 | 34 | 0.250 |
Why?
|
| Cognitive Dysfunction | 2 | 2020 | 309 | 0.250 |
Why?
|
| Europe | 7 | 2013 | 182 | 0.250 |
Why?
|
| Heart Arrest | 5 | 2021 | 161 | 0.250 |
Why?
|
| Sexuality | 2 | 2002 | 25 | 0.250 |
Why?
|
| Cholesterol | 4 | 2021 | 252 | 0.250 |
Why?
|
| Analysis of Variance | 7 | 2018 | 589 | 0.250 |
Why?
|
| Postoperative Complications | 4 | 2014 | 1204 | 0.240 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 551 | 0.240 |
Why?
|
| Medical History Taking | 2 | 2002 | 65 | 0.240 |
Why?
|
| Noninvasive Ventilation | 2 | 2016 | 70 | 0.240 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2005 | 21 | 0.240 |
Why?
|
| Health Status | 4 | 2017 | 425 | 0.240 |
Why?
|
| Cognition Disorders | 2 | 2017 | 215 | 0.230 |
Why?
|
| Global Health | 5 | 2014 | 167 | 0.230 |
Why?
|
| Visual Fields | 2 | 2014 | 43 | 0.230 |
Why?
|
| Patient Transfer | 3 | 2020 | 90 | 0.230 |
Why?
|
| Anxiety | 3 | 2023 | 387 | 0.230 |
Why?
|
| Drug Therapy, Combination | 7 | 2010 | 451 | 0.220 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 159 | 0.220 |
Why?
|
| Respiration Disorders | 1 | 2004 | 23 | 0.220 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2017 | 114 | 0.220 |
Why?
|
| Leukocytosis | 1 | 2003 | 11 | 0.220 |
Why?
|
| Medical Records, Problem-Oriented | 2 | 2021 | 13 | 0.210 |
Why?
|
| Eye Movements | 2 | 2014 | 82 | 0.210 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 259 | 0.210 |
Why?
|
| Health Behavior | 3 | 2018 | 452 | 0.210 |
Why?
|
| South America | 4 | 2013 | 23 | 0.210 |
Why?
|
| Physicians | 2 | 2017 | 440 | 0.210 |
Why?
|
| Hospices | 1 | 2023 | 34 | 0.210 |
Why?
|
| Demography | 6 | 2014 | 169 | 0.210 |
Why?
|
| Adenoma | 1 | 2023 | 64 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 4 | 2016 | 705 | 0.210 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 34 | 0.210 |
Why?
|
| Esophagitis | 1 | 2022 | 8 | 0.210 |
Why?
|
| North America | 4 | 2013 | 105 | 0.200 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 43 | 0.200 |
Why?
|
| Peptic Ulcer | 1 | 2022 | 20 | 0.200 |
Why?
|
| Dyspnea | 2 | 2016 | 116 | 0.200 |
Why?
|
| Tendinopathy | 2 | 2014 | 10 | 0.200 |
Why?
|
| Hyperkalemia | 1 | 2022 | 19 | 0.200 |
Why?
|
| Hospice Care | 1 | 2023 | 62 | 0.200 |
Why?
|
| India | 3 | 2020 | 150 | 0.200 |
Why?
|
| Gastroesophageal Reflux | 1 | 2022 | 82 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 52 | 0.190 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 27 | 0.190 |
Why?
|
| Syndrome | 11 | 2007 | 170 | 0.190 |
Why?
|
| Validation Studies as Topic | 2 | 2012 | 19 | 0.190 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 35 | 0.190 |
Why?
|
| Heart Conduction System | 1 | 2002 | 50 | 0.190 |
Why?
|
| Erectile Dysfunction | 1 | 2002 | 22 | 0.190 |
Why?
|
| Mitral Valve Prolapse | 1 | 2021 | 11 | 0.190 |
Why?
|
| Social Support | 2 | 2021 | 355 | 0.190 |
Why?
|
| Clinical Laboratory Services | 1 | 2021 | 5 | 0.190 |
Why?
|
| Hypotension | 2 | 2013 | 48 | 0.190 |
Why?
|
| Obstetric Labor Complications | 1 | 2021 | 24 | 0.190 |
Why?
|
| Heart Diseases | 2 | 2019 | 206 | 0.190 |
Why?
|
| Medical Laboratory Personnel | 1 | 2021 | 8 | 0.190 |
Why?
|
| Piperazines | 1 | 2002 | 74 | 0.190 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2021 | 31 | 0.190 |
Why?
|
| Dog Diseases | 1 | 2022 | 53 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2023 | 129 | 0.180 |
Why?
|
| Ambulatory Care Facilities | 1 | 2002 | 101 | 0.180 |
Why?
|
| Community Health Services | 3 | 2012 | 120 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 54 | 0.180 |
Why?
|
| Continuity of Patient Care | 3 | 2014 | 170 | 0.180 |
Why?
|
| Patient Compliance | 3 | 2021 | 349 | 0.180 |
Why?
|
| House Calls | 1 | 2020 | 18 | 0.180 |
Why?
|
| Rheumatic Heart Disease | 1 | 2020 | 7 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 132 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 305 | 0.170 |
Why?
|
| Mobility Limitation | 1 | 2020 | 47 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2024 | 191 | 0.170 |
Why?
|
| Occupational Diseases | 2 | 2014 | 263 | 0.170 |
Why?
|
| Patients | 1 | 2021 | 103 | 0.170 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 306 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 2 | 2015 | 130 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2021 | 187 | 0.170 |
Why?
|
| Cardiology | 1 | 2002 | 163 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2020 | 405 | 0.170 |
Why?
|
| Insurance Claim Review | 3 | 2015 | 76 | 0.170 |
Why?
|
| Renal Insufficiency | 2 | 2012 | 65 | 0.170 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2014 | 236 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 3 | 2019 | 90 | 0.160 |
Why?
|
| Aftercare | 2 | 2018 | 69 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 2 | 2024 | 45 | 0.160 |
Why?
|
| Models, Cardiovascular | 2 | 2011 | 76 | 0.160 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2014 | 297 | 0.160 |
Why?
|
| Musculoskeletal Diseases | 1 | 2020 | 101 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 22 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 64 | 0.160 |
Why?
|
| Schools | 1 | 2020 | 150 | 0.160 |
Why?
|
| Pharmacists | 1 | 2020 | 123 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2025 | 1118 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 147 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2019 | 914 | 0.160 |
Why?
|
| Hematocrit | 2 | 2011 | 32 | 0.160 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.150 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.150 |
Why?
|
| New Zealand | 4 | 2013 | 37 | 0.150 |
Why?
|
| Adipose Tissue | 2 | 2011 | 283 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 71 | 0.150 |
Why?
|
| Blepharoptosis | 1 | 2018 | 4 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 2020 | 131 | 0.150 |
Why?
|
| Publication Bias | 1 | 2018 | 20 | 0.150 |
Why?
|
| Australia | 4 | 2013 | 86 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 250 | 0.150 |
Why?
|
| Independent Living | 1 | 2018 | 44 | 0.150 |
Why?
|
| Emergency Service, Hospital | 3 | 2022 | 1022 | 0.150 |
Why?
|
| Air Pollutants | 2 | 2009 | 76 | 0.150 |
Why?
|
| Absenteeism | 1 | 2017 | 38 | 0.140 |
Why?
|
| Poverty | 3 | 2006 | 283 | 0.140 |
Why?
|
| Herpes Zoster | 1 | 2017 | 23 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 145 | 0.140 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 398 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 228 | 0.140 |
Why?
|
| Cost of Illness | 2 | 2015 | 156 | 0.140 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 411 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 136 | 0.140 |
Why?
|
| Smartphone | 1 | 2017 | 64 | 0.140 |
Why?
|
| Nurse's Role | 1 | 2017 | 116 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 74 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 149 | 0.130 |
Why?
|
| Workplace | 2 | 2011 | 169 | 0.130 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 89 | 0.130 |
Why?
|
| Interviews as Topic | 2 | 2013 | 484 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 284 | 0.130 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 292 | 0.130 |
Why?
|
| Glucocorticoids | 2 | 2015 | 179 | 0.130 |
Why?
|
| Activities of Daily Living | 3 | 2024 | 289 | 0.130 |
Why?
|
| Health Care Rationing | 1 | 2016 | 21 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2016 | 48 | 0.130 |
Why?
|
| Self Care | 1 | 2018 | 207 | 0.130 |
Why?
|
| Health Facility Size | 1 | 2015 | 16 | 0.130 |
Why?
|
| Pneumonia | 2 | 2016 | 281 | 0.130 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 19 | 0.130 |
Why?
|
| Culture | 1 | 2016 | 73 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 470 | 0.120 |
Why?
|
| Stearoyl-CoA Desaturase | 2 | 2011 | 9 | 0.120 |
Why?
|
| Creatinine | 2 | 2016 | 128 | 0.120 |
Why?
|
| Diplopia | 1 | 2014 | 9 | 0.120 |
Why?
|
| Fertility | 1 | 2015 | 78 | 0.120 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2019 | 349 | 0.120 |
Why?
|
| Genotype | 2 | 2014 | 617 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 102 | 0.120 |
Why?
|
| Optic Nerve | 1 | 2014 | 25 | 0.120 |
Why?
|
| Adalimumab | 1 | 2014 | 30 | 0.120 |
Why?
|
| Mental Recall | 1 | 2015 | 88 | 0.120 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 69 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 177 | 0.110 |
Why?
|
| Information Storage and Retrieval | 1 | 2014 | 60 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2014 | 48 | 0.110 |
Why?
|
| Health Care Surveys | 3 | 2010 | 277 | 0.110 |
Why?
|
| Aortic Rupture | 1 | 2014 | 54 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2014 | 7 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2014 | 17 | 0.110 |
Why?
|
| Hostility | 1 | 2014 | 15 | 0.110 |
Why?
|
| Executive Function | 1 | 2014 | 61 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 148 | 0.110 |
Why?
|
| Wrist | 1 | 2014 | 33 | 0.110 |
Why?
|
| Self Concept | 1 | 2014 | 105 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2016 | 207 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2018 | 417 | 0.110 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 3 | 0.110 |
Why?
|
| False Negative Reactions | 1 | 2013 | 40 | 0.110 |
Why?
|
| Visual Acuity | 1 | 2014 | 117 | 0.110 |
Why?
|
| Medicaid | 1 | 2017 | 353 | 0.110 |
Why?
|
| Aggression | 1 | 2014 | 52 | 0.110 |
Why?
|
| Psychomotor Performance | 1 | 2014 | 133 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2014 | 365 | 0.110 |
Why?
|
| Brain Hemorrhage, Traumatic | 1 | 2013 | 4 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 1559 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2013 | 42 | 0.110 |
Why?
|
| Reoperation | 1 | 2014 | 272 | 0.110 |
Why?
|
| Heart Ventricles | 2 | 2007 | 253 | 0.110 |
Why?
|
| Weight Gain | 1 | 2014 | 163 | 0.110 |
Why?
|
| Posture | 1 | 2014 | 127 | 0.110 |
Why?
|
| Sexism | 1 | 2013 | 29 | 0.110 |
Why?
|
| Glasgow Coma Scale | 1 | 2013 | 43 | 0.110 |
Why?
|
| Encephalocele | 1 | 2013 | 15 | 0.110 |
Why?
|
| Brain Edema | 1 | 2013 | 31 | 0.100 |
Why?
|
| Ticlopidine | 2 | 2011 | 45 | 0.100 |
Why?
|
| Fever | 1 | 2013 | 63 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 41 | 0.100 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 14 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 1091 | 0.100 |
Why?
|
| Injury Severity Score | 1 | 2013 | 101 | 0.100 |
Why?
|
| Cold Temperature | 1 | 2013 | 51 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 25 | 0.100 |
Why?
|
| International Cooperation | 2 | 2004 | 84 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2013 | 126 | 0.100 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2013 | 46 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 332 | 0.100 |
Why?
|
| Menopause | 2 | 2007 | 249 | 0.100 |
Why?
|
| Calcium Signaling | 1 | 2014 | 153 | 0.100 |
Why?
|
| Postpartum Period | 1 | 2014 | 187 | 0.100 |
Why?
|
| Tachycardia | 1 | 2012 | 28 | 0.100 |
Why?
|
| Health Personnel | 1 | 2016 | 342 | 0.100 |
Why?
|
| Ambulatory Care | 2 | 2006 | 303 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2013 | 80 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 98 | 0.100 |
Why?
|
| Los Angeles | 1 | 2012 | 11 | 0.100 |
Why?
|
| Artificial Intelligence | 1 | 2014 | 154 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2012 | 457 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 331 | 0.100 |
Why?
|
| International Classification of Diseases | 4 | 2014 | 131 | 0.100 |
Why?
|
| Injections | 1 | 2012 | 75 | 0.100 |
Why?
|
| Electric Countershock | 1 | 2012 | 99 | 0.100 |
Why?
|
| Tobacco Products | 1 | 2012 | 71 | 0.100 |
Why?
|
| Middle East | 1 | 2011 | 6 | 0.100 |
Why?
|
| Cross Infection | 1 | 2013 | 149 | 0.090 |
Why?
|
| Sleep | 1 | 2014 | 215 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 588 | 0.090 |
Why?
|
| Neoplasms | 2 | 2013 | 1231 | 0.090 |
Why?
|
| Brain Ischemia | 2 | 2013 | 399 | 0.090 |
Why?
|
| Angioplasty | 1 | 2011 | 51 | 0.090 |
Why?
|
| Mechanical Thrombolysis | 1 | 2011 | 35 | 0.090 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2007 | 23 | 0.090 |
Why?
|
| Homeostasis | 1 | 2014 | 346 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2012 | 133 | 0.090 |
Why?
|
| Hyaluronic Acid | 1 | 2012 | 66 | 0.090 |
Why?
|
| Wrist Injuries | 1 | 2011 | 12 | 0.090 |
Why?
|
| Consensus | 1 | 2012 | 193 | 0.090 |
Why?
|
| Particle Size | 1 | 2012 | 395 | 0.090 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2010 | 15 | 0.090 |
Why?
|
| Developing Countries | 3 | 2019 | 86 | 0.090 |
Why?
|
| Probability | 2 | 2008 | 167 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2012 | 180 | 0.090 |
Why?
|
| Women | 1 | 2011 | 43 | 0.090 |
Why?
|
| Dogs | 2 | 2022 | 314 | 0.090 |
Why?
|
| Vehicle Emissions | 2 | 2009 | 21 | 0.090 |
Why?
|
| Awards and Prizes | 1 | 2011 | 32 | 0.090 |
Why?
|
| Vena Cava Filters | 1 | 2010 | 23 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2012 | 141 | 0.090 |
Why?
|
| Edema | 1 | 2010 | 42 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2024 | 1792 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2011 | 146 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 333 | 0.080 |
Why?
|
| New England | 1 | 2010 | 267 | 0.080 |
Why?
|
| Sodium, Dietary | 1 | 2009 | 9 | 0.080 |
Why?
|
| Australasia | 2 | 2013 | 6 | 0.080 |
Why?
|
| Publishing | 1 | 2011 | 89 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2010 | 176 | 0.080 |
Why?
|
| Environmental Exposure | 2 | 2009 | 209 | 0.080 |
Why?
|
| Metoprolol | 1 | 2009 | 11 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2009 | 715 | 0.080 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2009 | 12 | 0.080 |
Why?
|
| Boston | 2 | 2012 | 245 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 439 | 0.080 |
Why?
|
| Patient-Centered Care | 2 | 2020 | 246 | 0.080 |
Why?
|
| Glucose | 1 | 2012 | 445 | 0.080 |
Why?
|
| Carbon | 1 | 2009 | 45 | 0.080 |
Why?
|
| Pandemics | 2 | 2024 | 616 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2012 | 392 | 0.080 |
Why?
|
| Echinocandins | 1 | 2008 | 3 | 0.080 |
Why?
|
| Orbital Diseases | 1 | 2008 | 9 | 0.080 |
Why?
|
| Mucormycosis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Amphotericin B | 1 | 2008 | 21 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2011 | 458 | 0.080 |
Why?
|
| Polyvinyl Chloride | 1 | 2008 | 2 | 0.080 |
Why?
|
| Sepsis | 1 | 2012 | 272 | 0.080 |
Why?
|
| Rhinitis | 1 | 2008 | 22 | 0.080 |
Why?
|
| Heparin | 2 | 2007 | 111 | 0.080 |
Why?
|
| Audiovisual Aids | 1 | 2008 | 11 | 0.070 |
Why?
|
| Sus scrofa | 1 | 2008 | 27 | 0.070 |
Why?
|
| Income | 2 | 2019 | 157 | 0.070 |
Why?
|
| Motor Vehicles | 1 | 2008 | 35 | 0.070 |
Why?
|
| Consumer Behavior | 1 | 2008 | 35 | 0.070 |
Why?
|
| Cough | 1 | 2010 | 183 | 0.070 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 608 | 0.070 |
Why?
|
| Air Pollution | 1 | 2008 | 29 | 0.070 |
Why?
|
| Bronchi | 1 | 2008 | 82 | 0.070 |
Why?
|
| Drug Information Services | 1 | 2007 | 5 | 0.070 |
Why?
|
| Trachea | 1 | 2008 | 91 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2008 | 120 | 0.070 |
Why?
|
| Pulmonary Medicine | 1 | 2008 | 40 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2008 | 57 | 0.070 |
Why?
|
| Mass Media | 1 | 2007 | 31 | 0.070 |
Why?
|
| Costa Rica | 3 | 2013 | 5 | 0.070 |
Why?
|
| Community Health Workers | 2 | 2020 | 37 | 0.070 |
Why?
|
| Upper Extremity | 1 | 2007 | 49 | 0.070 |
Why?
|
| Enoxaparin | 1 | 2007 | 17 | 0.070 |
Why?
|
| Life Tables | 1 | 2007 | 23 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2007 | 64 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 329 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 26 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2007 | 123 | 0.070 |
Why?
|
| Canada | 3 | 2014 | 147 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2005 | 34 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2006 | 52 | 0.060 |
Why?
|
| Internal Medicine | 1 | 2007 | 154 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2013 | 720 | 0.060 |
Why?
|
| Arteries | 1 | 2006 | 76 | 0.060 |
Why?
|
| Poisson Distribution | 2 | 2016 | 52 | 0.060 |
Why?
|
| Spironolactone | 1 | 2005 | 9 | 0.060 |
Why?
|
| District of Columbia | 1 | 2005 | 9 | 0.060 |
Why?
|
| New York City | 1 | 2005 | 75 | 0.060 |
Why?
|
| Family Practice | 1 | 2007 | 207 | 0.060 |
Why?
|
| Occupational Health Services | 1 | 2005 | 36 | 0.060 |
Why?
|
| Education | 1 | 2005 | 68 | 0.060 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 157 | 0.060 |
Why?
|
| Health Services Research | 3 | 2012 | 266 | 0.060 |
Why?
|
| Medicare Part B | 1 | 2004 | 11 | 0.060 |
Why?
|
| Geriatric Nursing | 1 | 2024 | 49 | 0.060 |
Why?
|
| Animals | 4 | 2022 | 19649 | 0.060 |
Why?
|
| Hunger | 1 | 2004 | 14 | 0.060 |
Why?
|
| Maternal Age | 1 | 2024 | 32 | 0.060 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2003 | 3 | 0.060 |
Why?
|
| Transportation | 1 | 2004 | 32 | 0.050 |
Why?
|
| Cardiac Output, Low | 1 | 2003 | 10 | 0.050 |
Why?
|
| Internet | 1 | 2007 | 448 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 2903 | 0.050 |
Why?
|
| Triglycerides | 1 | 2005 | 231 | 0.050 |
Why?
|
| Food Supply | 1 | 2004 | 51 | 0.050 |
Why?
|
| Quarantine | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cathartics | 1 | 2023 | 8 | 0.050 |
Why?
|
| Housing | 1 | 2004 | 72 | 0.050 |
Why?
|
| Suppuration | 1 | 2023 | 11 | 0.050 |
Why?
|
| Occupational Health | 1 | 2005 | 181 | 0.050 |
Why?
|
| Ulcer | 1 | 2023 | 14 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2022 | 20 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2023 | 86 | 0.050 |
Why?
|
| Manometry | 1 | 2022 | 22 | 0.050 |
Why?
|
| Markov Chains | 1 | 2002 | 34 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2002 | 35 | 0.050 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2022 | 68 | 0.050 |
Why?
|
| Stents | 2 | 2004 | 461 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 100 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 131 | 0.050 |
Why?
|
| Physical Examination | 2 | 2014 | 104 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2002 | 11 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2002 | 53 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2002 | 37 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2002 | 42 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2002 | 54 | 0.050 |
Why?
|
| Contraindications | 1 | 2002 | 46 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 37 | 0.050 |
Why?
|
| Sulfones | 1 | 2002 | 36 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 1 | 2002 | 77 | 0.050 |
Why?
|
| Purines | 1 | 2002 | 38 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2002 | 68 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2022 | 74 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 288 | 0.050 |
Why?
|
| Exercise Test | 1 | 2003 | 242 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 85 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2007 | 647 | 0.050 |
Why?
|
| Postmenopause | 1 | 2002 | 224 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 135 | 0.040 |
Why?
|
| Mothers | 1 | 2004 | 256 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 18 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2020 | 7 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 126 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2022 | 400 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 115 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 61 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2004 | 619 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2024 | 682 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 88 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 313 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 1283 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1491 | 0.040 |
Why?
|
| Peptides | 1 | 2002 | 549 | 0.040 |
Why?
|
| Family | 1 | 2020 | 229 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 61 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 525 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2020 | 126 | 0.040 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.040 |
Why?
|
| Patient Safety | 1 | 2020 | 237 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2016 | 30 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 52 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 185 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 519 | 0.030 |
Why?
|
| Epidemiologic Methods | 2 | 2006 | 65 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 32 | 0.030 |
Why?
|
| Internationality | 1 | 2014 | 43 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 122 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2014 | 73 | 0.030 |
Why?
|
| Emergencies | 1 | 2014 | 110 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 112 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 931 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 403 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 61 | 0.030 |
Why?
|
| Occupations | 1 | 2014 | 51 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2013 | 9 | 0.030 |
Why?
|
| Proteinuria | 1 | 2013 | 38 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 126 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 144 | 0.030 |
Why?
|
| History, Ancient | 1 | 2013 | 11 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 242 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 371 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2012 | 134 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 141 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2011 | 4 | 0.020 |
Why?
|
| Confidentiality | 1 | 2012 | 52 | 0.020 |
Why?
|
| Haplotypes | 1 | 2011 | 115 | 0.020 |
Why?
|
| San Francisco | 1 | 2011 | 10 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 137 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 58 | 0.020 |
Why?
|
| Iliac Artery | 1 | 2011 | 49 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 190 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 411 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2012 | 337 | 0.020 |
Why?
|
| Samoa | 1 | 2009 | 3 | 0.020 |
Why?
|
| Nomograms | 1 | 2009 | 12 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2008 | 41 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2008 | 15 | 0.020 |
Why?
|
| Energy Intake | 1 | 2009 | 167 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2009 | 173 | 0.020 |
Why?
|
| Dissent and Disputes | 1 | 2007 | 7 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 37 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 805 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2007 | 84 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 206 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 795 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2007 | 189 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2007 | 152 | 0.020 |
Why?
|
| Triage | 1 | 2006 | 108 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 33 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2006 | 84 | 0.010 |
Why?
|
| Pyridines | 1 | 2005 | 98 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2005 | 59 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 1552 | 0.010 |
Why?
|
| Drug Costs | 1 | 2005 | 54 | 0.010 |
Why?
|
| Americas | 1 | 2004 | 5 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2004 | 38 | 0.010 |
Why?
|
| Streptokinase | 1 | 2004 | 6 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 2004 | 14 | 0.010 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2004 | 4 | 0.010 |
Why?
|
| Public Assistance | 1 | 2004 | 9 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 2004 | 43 | 0.010 |
Why?
|
| Resuscitation | 1 | 2004 | 70 | 0.010 |
Why?
|
| Child Welfare | 1 | 2004 | 52 | 0.010 |
Why?
|
| Parenting | 1 | 2004 | 67 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2005 | 202 | 0.010 |
Why?
|
| Argentina | 1 | 2002 | 7 | 0.010 |
Why?
|
| Diastole | 1 | 2003 | 89 | 0.010 |
Why?
|
| Brazil | 1 | 2002 | 88 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2002 | 5 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2002 | 14 | 0.010 |
Why?
|
| Family Characteristics | 1 | 2002 | 43 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2002 | 65 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2002 | 135 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2002 | 144 | 0.010 |
Why?
|
| Software | 1 | 2003 | 366 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 414 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 1098 | 0.010 |
Why?
|